Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Functionalizing Liposomes with Dual Aptamers for Targeting of Breast Cancer Cells and Cancer Stem Cells

  • Park, Hee-Bin (Department of Biomedical Laboratory Science, Konyang University) ;
  • You, Ji-Eun (Department of Biomedical Laboratory Science, Konyang University) ;
  • Kim, Pyung-Hwan (Department of Biomedical Laboratory Science, Konyang University) ;
  • Kim, Keun-Sik (Department of Biomedical Laboratory Science, Konyang University)
  • Received : 2021.02.18
  • Accepted : 2021.03.18
  • Published : 2021.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Cancer stem cells, which are known to drive tumor formation and maintenance, are a major obstacle in the effective treatment of various types of cancer. Trans-membrane glycoprotein mucin 1 antigen and cell surface glycogen CD44 antigen are well-known surface markers of breast cancer cells and breast cancer stem cells, respectively. To effectively treat cancer cells and cancer stem cells, we developed a new drug-encapsulating liposome conjugated with dual-DNA aptamers specific to the surface markers of breast cancer cells and their cancer stem cells. These two aptamer (Apt)-targeted liposomes, which were prepared to encapsulate doxorubicin (Dox), were named "Dual-Apt-Dox". Dual-Apt-Dox is significantly more cytotoxic to both cancer stem cells and cancer cells compared to liposomes lacking the aptamers. Furthermore, we demonstrated the inhibitory efficacy of Dual-Apt-Dox against the experimental lung metastasis of breast cancer stem cells and cancer cells in athymic nude mice. We also showed the potent antitumor effects of dual-aptamer-conjugated liposome systems by targeting cancer cells as well as cancer stem cells. Thus, our data indicate that dual-aptamer-conjugated liposome systems can prove to be effective drug delivery vehicles for breast cancer therapy.

Keywords

References

  1. Bayrac AT, Sefah K, Parekh P, Bayrac C, Gulbakan B, Oktem HA, Tan W. In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chemical Neuroscience. 2011. 2: 175-181. https://doi.org/10.1021/cn100114k
  2. Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: A comprehensive review of literature. Journal of Cancer Research and Clinical Oncology. 2015. 141: 769-784. https://doi.org/10.1007/s00432-014-1767-3
  3. ComSa S, Cimpean AM, Raica M. The story of mcf-7 breast cancer cell line: 40 years of experience in research. Anticancer Research. 2015. 35: 3147-3154.
  4. Crabtree JS, Miele L. Breast cancer stem cells. Biomedicines. 2018. 6: 77. https://doi.org/10.3390/biomedicines6030077
  5. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: Models and concepts. Annu Rev Med. 2007. 58: 267-284. https://doi.org/10.1146/annurev.med.58.062105.204854
  6. Fan C, Georgiou KR, Morris HA, McKinnon RA, Keefe DM, Howe PR, Xian CJ. Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model. Breast Cancer Research and Treatment. 2017. 165: 41-51. https://doi.org/10.1007/s10549-017-4308-3
  7. Ghannam MM, El Gebaly R, Fadel M. Targeting doxorubicin encapsulated in stealth liposomes to solid tumors by non thermal diode laser. Lipids in Health and Disease. 2016. 15: 1-8. https://doi.org/10.1186/s12944-015-0172-5
  8. Group ES. Preclinical and phase 1a clinical evaluation of an anti-vegf pegylated aptamer (eye001) for the treatment of exudative age-related macular degeneration. Retina. 2002. 22: 143 -152. https://doi.org/10.1097/00006982-200204000-00002
  9. Guan J, Shen Q, Zhang Z, Jiang Z, Yang Y, Lou M, Qian J, Lu W, Zhan C. Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural igm absorption. Nature Communications. 2018. 9: 1-11. https://doi.org/10.1038/s41467-017-02088-w
  10. Khodabandehloo H, Zahednasab H, Hafez AA. Nanocarriers usage for drug delivery in cancer therapy. Iranian Journal of Cancer Prevention. 2016. 9.
  11. Kim M, Kim DM, Kim KS, Jung W, Kim DE. Applications of cancer cell-specific aptamers in targeted delivery of anticancer therapeutic agents. Molecules. 2018. 23: 830. https://doi.org/10.3390/molecules23040830
  12. Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, Deng Y. A review on phospholipids and their main applications in drug delivery systems. Asian Journal of Pharmaceutical Sciences. 2015. 10: 81-98. https://doi.org/10.1016/j.ajps.2014.09.004
  13. Li R, Zheng K, Yuan C, Chen Z, Huang M. Be active or not: The relative contribution of active and passive tumor targeting of nanomaterials. Nanotheranostics. 2017. 1: 346. https://doi.org/10.7150/ntno.19380
  14. Lin X, Gao R, Zhang Y, Qi N, Zhang Y, Zhang K, He H, Tang X. Lipid nanoparticles for chemotherapeutic applications: Strategies to improve anticancer efficacy. Expert Opinion on Drug Delivery. 2012a. 9: 767-781. https://doi.org/10.1517/17425247.2012.685933
  15. Lin Y, Zhong Y, Guan H, Zhang X, Sun Q. Cd44+/cd24-phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. Journal of Experimental & Clinical Cancer Research. 2012b. 31: 59. https://doi.org/10.1186/1756-9966-31-59
  16. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. The Journal of Clinical Investigation. 2005. 115: 44-55. https://doi.org/10.1172/JCI22320
  17. Pasut G, Paolino D, Celia C, Mero A, Joseph AS, Wolfram J, Cosco D, Schiavon O, Shen H, Fresta M. Polyethylene glycol (peg)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. Journal of Controlled Release. 2015. 199: 106-113. https://doi.org/10.1016/j.jconrel.2014.12.008
  18. Patra JK, Das G, Fraceto LF, Campos EVR, del Pilar Rodriguez-Torres M, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S. Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology. 2018. 16: 71. https://doi.org/10.1186/s12951-018-0392-8
  19. Saw PE, Park J, Lee E, Ahn S, Lee J, Kim H, Kim J, Choi M, Farokhzad OC, Jon S. Effect of peg pairing on the efficiency of cancer-targeting liposomes. Theranostics. 2015. 5: 746. https://doi.org/10.7150/thno.10732
  20. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Badve S, Nakshatri H. Cd44+/cd24-breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Research. 2006. 8: 1-13. https://doi.org/10.1186/bcr1362
  21. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a Cancer Journal for Clinicians. 2016. 66: 7-30. https://doi.org/10.3322/caac.21332
  22. Sin WC, Lim CL. Breast cancer stem cells-from origins to targeted therapy. Stem Cell Investigation. 2017. 4. https://doi.org/10.21037/sci.2017.11.07
  23. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery. 2005. 4: 145-160. https://doi.org/10.1038/nrd1632
  24. Trebunova M, Laputkova G, Slaba E, Lacjakova K, Verebova A. Effects of docetaxel, doxorubicin and cyclophosphamide on human breast cancer cell line mcf-7. Anticancer Research. 2012. 32: 2849-2854.
  25. Xing H, Hwang K, Lu Y. Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics. 2016. 6: 1336. https://doi.org/10.7150/thno.15464
  26. Yan C, Luo L, Guo CY, Goto S, Urata Y, Shao JH, Li TS. Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from hct8 human colorectal cancer cells. Cancer Letters. 2017. 388: 34-42. https://doi.org/10.1016/j.canlet.2016.11.018
  27. Yi SY, Ahn JS, Uhm JE, Lim DH, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. BMC Cancer. 2010. 10: 527. https://doi.org/10.1186/1471-2407-10-527